Pharmacokinetic drug-drug interactions of tyrosine kinase inhibitors: A focus on cytochrome P450, transporters, and acid suppression therapy

Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population

(2016) Hannah Bower et al.   JOURNAL OF CLINICAL ONCOLOGY

Adverse event potentially due to an interaction between ibrutinib and verapamil: a case report

(2016) E. Lambert Kuhn et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Management of adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukemia

(2015) Delphine Rea   ANNALS OF HEMATOLOGY

Variability in bioavailability of small molecular tyrosine kinase inhibitors

(2015) Maikel Herbrink et al.   CANCER TREATMENT REVIEWS

Clinical Pharmacokinetic and Pharmacodynamic Profile of Idelalisib

(2015) Srinivasan Ramanathan et al.   CLINICAL PHARMACOKINETICS

Enzyme- and transporter-mediated beverage-drug interactions: An update on fruit juices and green tea

(2015) Guohua An et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Ingredients in Fruit Juices Interact with Dasatinib Through Inhibition of BCRP: A New Mechanism of Beverage-Drug Interaction

(2015) Brett Fleisher et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Genetic Polymorphisms and Function of the Organic Anion-Transporting Polypeptide 1A2 and Its Clinical Relevance in Drug Disposition

(2015) Yinhui Zhou et al.   PHARMACOLOGY

Impact ofCYP2C8*3polymorphism onin vitrometabolism of imatinib to N-desmethyl imatinib

(2015) Muhammad Suleman Khan et al.   XENOBIOTICA

Predicting Drug-Drug Interactions Involving Multiple Mechanisms Using Physiologically Based Pharmacokinetic Modeling: A Case Study With Ruxolitinib

(2015) JG Shi et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Role of the Breast Cancer Resistance Protein (BCRP/ABCG2) in Drug Transport—an Update

(2014) Qingcheng Mao et al.   AAPS Journal

Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro–in vivo correlations

(2014) S Hu et al.   BRITISH JOURNAL OF CANCER

Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor

(2014) Dong-Hoe Koo et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjects

(2014) Marta Hamilton et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: Comparative pharmacokinetics and drug–drug interactions

(2014) Solange Peters et al.   CANCER TREATMENT REVIEWS

Pharmacokinetic Drug Interactions of Afatinib with Rifampicin and Ritonavir

(2014) Sven Wind et al.   CLINICAL DRUG INVESTIGATION

Pharmacokinetic Evaluations of the Co-Administrations of Vandetanib and Metformin, Digoxin, Midazolam, Omeprazole or Ranitidine

(2014) Susanne Johansson et al.   CLINICAL PHARMACOKINETICS

pH-Dependent Drug–Drug Interactions for Weak Base Drugs: Potential Implications for New Drug Development

(2014) L Zhang et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Enzyme-Transporter-Mediated Drug Interactions with Small Molecule Tyrosine Kinase Inhibitors

(2014) Jie Shao et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Drug–drug interactions with tyrosine-kinase inhibitors: a clinical perspective

(2014) Roelof W F van Leeuwen et al.   LANCET ONCOLOGY

Drug interactions between tyrosine-kinase inhibitors and acid suppressive agents: more than meets the eye

(2014) Guo Yu et al.   LANCET ONCOLOGY

Determining the optimal dose in the development of anticancer agents

(2014) Ron H. J. Mathijssen et al.   Nature Reviews Clinical Oncology

ABC Transporters in Multi-Drug Resistance and ADME-Tox of Small Molecule Tyrosine Kinase Inhibitors

(2014) Jiexin Deng et al.   PHARMACEUTICAL RESEARCH

Sunitinib in combination with clarithromycin or azithromycin – is there a risk of interaction or not?

(2014) Edyta Szałek et al.   Pharmacological Reports

Pharmacokinetics of sunitinib in combination with fluoroquinolones in rabbit model

(2014) Edyta Szałek et al.   Pharmacological Reports

Pharmacokinetic Drug Interaction Between Cyclosporine and Imatinib in Bone Marrow Transplant Children and Model-Based Reappraisal of Imatinib Drug Interaction Profile

(2014) Nathalie Bleyzac et al.   THERAPEUTIC DRUG MONITORING

Crizotinib: A New Treatment Option for ALK-Positive Non-Small Cell Lung Cancer

(2013) Cindy L O'Bryant et al.   ANNALS OF PHARMACOTHERAPY

Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors

(2013) Antoinette R. Tan et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Relevance of in vitro and clinical data for predicting CYP3A4-mediated herb–drug interactions in cancer patients

(2013) Andrew K.L. Goey et al.   CANCER TREATMENT REVIEWS

Gemfibrozil Impairs Imatinib Absorption and Inhibits the CYP2C8-Mediated Formation of Its Main Metabolite

(2013) A M Filppula et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Drug interactions with solid tumour-targeted therapies

(2013) Audrey Thomas-Schoemann et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Differential effects of ketoconazole, itraconazole and voriconazole on the pharmacokinetics of imatinib and its main metabolite GCP74588 in rat

(2013) Gaotong Lin et al.   DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY

Effect of the ATP-binding cassette transporter ABCG2 on pharmacokinetics: experimental findings and clinical implications

(2013) Rebecca Schnepf et al.   Expert Opinion on Drug Metabolism & Toxicology

Interactions between oral antineoplastic agents and concomitant medication: a systematic review

(2013) Esther Carcelero et al.   Expert Opinion On Drug Safety

Twelve-Month Frequency of Drug-Metabolizing Enzyme and Transporter-Based Drug-Drug Interaction Potential in Patients Receiving Oral Enzyme-Targeted Kinase Inhibitor Antineoplastic Agents

(2013) Steven J. Bowlin et al.   MAYO CLINIC PROCEEDINGS

Prevalence of Acid-Reducing Agents (ARA) in Cancer Populations and ARA Drug–Drug Interaction Potential for Molecular Targeted Agents in Clinical Development

(2013) Gillian S. Smelick et al.   MOLECULAR PHARMACEUTICS

The association of cytochrome P450 genetic polymorphisms with sulfolane formation and the efficacy of a busulfan-based conditioning regimen in pediatric patients undergoing hematopoietic stem cell transplantation

(2013) C R S Uppugunduri et al.   PHARMACOGENOMICS JOURNAL

Pharmacokinetic Drug Interactions with Vandetanib during Coadministration with Rifampicin or Itraconazole

(2013) Paul Martin et al.   Drugs in research & development

Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia

(2012) Elias J. Jabbour et al.   AMERICAN JOURNAL OF HEMATOLOGY

Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients

(2012) S. J. Seong et al.   ANNALS OF ONCOLOGY

Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer

(2012) Tomohiro Suzumura et al.   BMC CANCER

Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2

(2012) E Brain et al.   BRITISH JOURNAL OF CANCER

Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein

(2012) Wen-jing Zhou et al.   BRITISH JOURNAL OF PHARMACOLOGY

Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft models

(2012) Amit K. Tiwari et al.   CANCER LETTERS

Drug Absorption Interactions Between Oral Targeted Anticancer Agents and PPIs: Is pH-Dependent Solubility the Achilles Heel of Targeted Therapy?

(2012) N R Budha et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Ascending Single-Dose Study of the Safety Profile, Tolerability, and Pharmacokinetics of Bosutinib Coadministered With Ketoconazole to Healthy Adult Subjects

(2012) Richat Abbas et al.   CLINICAL THERAPEUTICS

Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors

(2012) Mukul Minocha et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Nilotinib Counteracts P-Glycoprotein-Mediated Multidrug Resistance and Synergizes the Antitumoral Effect of Doxorubicin in Soft Tissue Sarcomas

(2012) Victor Hugo Villar et al.   PLoS One

Inhibition of paracetamol glucuronidation by tyrosine kinase inhibitors

(2011) Yong Liu et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Interaction of innovative small molecule drugs used for cancer therapy with drug transporters

(2011) K Mandery et al.   BRITISH JOURNAL OF PHARMACOLOGY

Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study

(2011) Keith T. Flaherty et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Two Drug Interaction Studies of Sirolimus in Combination with Sorafenib or Sunitinib in Patients with Advanced Malignancies

(2011) T. C. Gangadhar et al.   CLINICAL CANCER RESEARCH

Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors

(2011) Paola Di Gion et al.   CLINICAL PHARMACOKINETICS

The effect of grapefruit juice on drug disposition

(2011) Michael J Hanley et al.   Expert Opinion on Drug Metabolism & Toxicology

How Many Cancer Patients Use Complementary and Alternative Medicine

(2011) Markus Horneber et al.   INTEGRATIVE CANCER THERAPIES

The Effect of CYP3A4 Inhibition or Induction on the Pharmacokinetics and Pharmacodynamics of Orally Administered Ruxolitinib (INCB018424 Phosphate) in Healthy Volunteers

(2011) Jack G. Shi et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study

(2011) Jesus Garcia-Donas et al.   LANCET ONCOLOGY

Polypharmacy in elderly patients with cancer: clinical implications and management

(2011) Judith Lees et al.   LANCET ONCOLOGY

Drug-Induced Effects on Erlotinib Metabolism

(2011) Olivier Mir et al.   NEW ENGLAND JOURNAL OF MEDICINE

Elevated International Normalized Ratio associated with concomitant warfarin and erlotinib

(2010) K. S. Thomas et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Imatinib and Panax Ginseng: A Potential Interaction Resulting in Liver Toxicity

(2010) Naveen Bilgi et al.   ANNALS OF PHARMACOTHERAPY

Fruit juice inhibition of uptake transport: a new type of food-drug interaction

(2010) David G. Bailey   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors

(2010) Faye M. Johnson et al.   CANCER

Effects of Nilotinib on Single-Dose Warfarin Pharmacokinetics and Pharmacodynamics

(2010) Ophelia Q.P. Yin et al.   CLINICAL DRUG INVESTIGATION

Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma

(2010) Charline Gomo et al.   INVESTIGATIONAL NEW DRUGS

Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers

(2010) Yazdi K. Pithavala et al.   INVESTIGATIONAL NEW DRUGS

Effects of Rifampin and Ketoconazole on the Pharmacokinetics of Nilotinib in Healthy Participants

(2010) Chiaki Tanaka et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma

(2010) David A. Reardon et al.   JOURNAL OF NEURO-ONCOLOGY

Potential for drug–drug interactions in treating cancer-related nausea and distress

(2010) Matthew S Saylor et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Effects of ketoconazole and carbamazepine on lapatinib pharmacokinetics in healthy subjects

(2009) Deborah A. Smith et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Gefitinib-phenytoin interaction is not correlated with the14C-erythromycin breath test in healthy male volunteers

(2009) Stephanie Chhun et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers

(2009) Y. K. Pithavala et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Clinical pharmacokinetics of tyrosine kinase inhibitors

(2009) Nielka P. van Erp et al.   CANCER TREATMENT REVIEWS

Sorafenib

(2009) Gillian M. Keating et al.   DRUGS

Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034

(2009) Martin J. van den Bent et al.   JOURNAL OF CLINICAL ONCOLOGY

Mécanismes des interactions médicamenteuses d’origine pharmacocinétique

(2009) D. Levêque et al.   REVUE DE MEDECINE INTERNE

Evaluation of Lapatinib and Topotecan Combination Therapy: Tissue Culture, Murine Xenograft, and Phase I Clinical Trial Data

(2008) J. R. Molina et al.   CLINICAL CANCER RESEARCH

Rhabdomyolysis Resulting from Pharmacologic Interaction Between Erlotinib and Simvastatin

(2008) Muthu Veeraputhiran et al.   Clinical Lung Cancer

Drug–Drug Interactions Mediated Through P-Glycoprotein: Clinical Relevance and In Vitro–In Vivo Correlation Using Digoxin as a Probe Drug

(2008) KS Fenner et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Valproic acid enhances bosutinib cytotoxicity in colon cancer cells

(2008) Luca Mologni et al.   INTERNATIONAL JOURNAL OF CANCER

Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib

(2008) J. Ma et al.   MOLECULAR CANCER THERAPEUTICS